Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Logistic regression analysis identified prior neurologic event (P = .046), nonelective surgery (P = .047), absence of coronary artery disease (P = .035), and preoperative angiotensin-converting enzyme inhibitor use (P = .029) to be associated with 30-day ipsilateral stroke risk, but contralateral ICA occlusion remained an independent predictor in that model (odds ratio, 2.29; P = .026). 31445827 2020
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). 31370961 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE The results indicated that ACE INDEL polymorphism is an important predictor of coronary artery disease in Turkish Cypriots. 30414419 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Several small, short-term trials suggested benefit on albuminuria in subjects with diabetes; however, results were not definitive.Welty et al. showed that eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 1 year slowed progression of early-stage albuminuria in subjects with diabetes with clinical coronary artery disease on an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, the majority of whom had an albumin/creatinine ratio (ACR) < 30 μg/mg. 30684085 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE A higher prevalence of anemia in CHF due to coronary heart disease may be associated with wider use of angiotensin converting enzyme inhibitors and acetylsalicylic acid. 30697681 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Apolipoprotein B and angiotensin-converting enzyme polymorphisms and aerobic interval training: randomized controlled trial in coronary artery disease patients. 29846435 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Genetic polymorphisms of MMP-3 5A/6A and ACE I/D along with conventional ischaemic heart disease risk factors increase the risk of the occurrence of STEMI, while having no influence on the pathogenesis of NSTEMI. 29141503 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Advanced Strategies in the Diagnosis and Treatment of Patients with Coronary Artery Disease and Heart Failure: When Heart Failure Causes Ischemia and Angiotensin Converting Enzyme Inhibitor and Betablockers Helps in Diuresis. 29283057 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE These 11 therapies were for patients with heart failure (angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, aldosterone receptor antagonists and digoxin), stable coronary artery disease (intensive statin therapy), asthma exacerbations (early inhaled corticosteroids in the emergency department and anticholinergics), chronic obstructive pulmonary disease (long-acting muscarinic antagonists and long-acting beta-2 adrenoceptor agonists) and schizophrenia (second-generation antipsychotics and depot/maintenance antipsychotics). 30045724 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea. 30225928 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE The Effect of ACE I/D Polymorphisms Alone and With Concomitant Risk Factors on Coronary Artery Disease. 27895197 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Prior stroke/TIA and/or PAD patients were less likely to receive evidence-based medical therapies (dual antiplatelet therapy: stroke/TIA= 88.6%, PAD= 86.6%, stroke/TIA+PAD= 85.7%, none= 92.2%, p<0.001; β-blockers: stroke/TIA= 77.1%, PAD= 72.1%, stroke/TIA+PAD= 71.9%, none= 80.8%, p<0.001; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: stroke/TIA= 86.3%, PAD= 83.6%, stroke/TIA+PAD= 83.2%, none= 87.1%, p=0.030) and to undergo percutaneous revascularization (stroke/TIA= 52.8%, PAD= 45.6%, stroke/TIA+PAD= 43.7%, none= 67.9%, p<0.001), despite more extensive coronary artery disease (three-vessel disease: stroke/TIA= 29.1%, PAD= 38.3%, stroke/TIA+PAD= 38.3%, none= 20.2%, p<0.001). 28627932 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease. 28710178 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE The communal relation of MTHFR, MTR, ACE gene polymorphisms and hyperhomocysteinemia as conceivable risk of coronary artery disease. 28514598 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Before hospital admission, 84% of patients had antiplatelet therapy compared with 96% at discharge (P = 0.0004); 73% had a statin, compared with 83% at discharge (P = 0.001); 64% had an ACE inhibitor or ARB, compared with 63% at the time of discharge (P = 1).The proportion of patients receiving best medical treatment at admission and discharge increased in case of coronary artery disease (P = 0.004). 27908822 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Thus, our study suggests that genetic polymorphisms of angiotensin-converting enzyme insertion/deletion are associated with in-stent restenosis in coronary artery disease patients following coronary stenting. 28196432 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic impact (from the CORONOR study). 27283338 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE There is strong evidence to suggest that angiotensin-converting enzyme inhibitors (ACEIs) protect against local myocardial ischemia/reperfusion (I/R) injury. 27633002 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Relationship of the rs1799752 polymorphism of the angiotensin-converting enzyme gene and the rs699 polymorphism of the angiotensinogen gene to the process of in-stent restenosis in a population of Polish patients with stable coronary artery disease. 27162064 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Association between angiotensin-converting-enzyme (ACE) gene polymorphisms and different clinical and echocardiographic outcomes has been described in patients with heart failure (HF) and coronary artery disease. 27812677 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. 27021566 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Angiotensin I-converting enzyme gene polymorphism enhances the effect of hypercholesterolemia on the risk of coronary heart disease in a general Japanese population: the hisayama study. 25342476 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease. 24505095 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 Biomarker disease BEFREE We assessed ACE plasma concentration in 73 patients with acute thoracic aortic dissection (n=34), aneurysm (n=18), coronary heart disease (n=21) and 13 healthy volunteers. 25237166 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.400 GeneticVariation disease BEFREE Traditional risk factors and angiotensin-converting enzyme insertion/deletion gene polymorphism in coronary artery disease. 25867352 2015